<DOC>
	<DOCNO>NCT00398684</DOCNO>
	<brief_summary>The purpose study assess efficacy single dose drug nevirapine ( NVP ) give pregnant woman onset labor infant 48-72 hour birth addition standard oral zidovudine ( ZDV AZT ) prophylaxis prevention mother-to-child transmission HIV-1 .</brief_summary>
	<brief_title>Nevirapine Plus Zidovudine Prevent Perinatal HIV Thailand</brief_title>
	<detailed_description>Multicenter , randomize , three arm , double-blind , control study . Study population HIV-infected pregnant woman ZDV prophylaxis two week give inform consent . If eligible , woman complete baseline check-up . Women meet selection criterion randomly assign receive one three study regimen , addition ZDV prophylaxis : 1 . One dose maternal NVP treatment onset labor , one dose infant NVP treatment 48-72 hour birth 2 . One dose maternal NVP treatment onset labor , one dose infant placebo 48-72 hour birth 3 . One dose maternal placebo onset labor , one dose infant placebo 48-72 hour birth . This reference study arm . Follow-up woman infant carry outpatient basis except delivery first three day delivery . AMENDMENT After first interim analysis , enrollment Placebo-Placebo arm terminate May 2 , 2002 , accord recommendation Data Safety Monitoring Board . The target sample size increase 660 , instead 510 , two remain arm ( N-N N-P ) ensure enough power test non-inferiority arm limit 2.5 % .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>PreEntry Criteria Women eligible study : evidence HIV infection ( document two HIV antibody test two different date ) ; provide ZDV Prophylaxis ( start 28 week soon possible thereafter ) ; intend carry pregnancy term ; intend deliver bring infant study site least 12 month delivery ; could provide informed consent . Inclusion criterion Women eligible study : meet preentry criterion ; agree breastfeed ; consent participate follow duration study ; present follow laboratory value within 14 day prior randomization : hemoglobin &gt; 8.0 mg/dl absolute neutrophil count &gt; 1000 cells/mm3 platelet &gt; 100,000 cells/mm3 serum creatinine &lt; 1.5 mg/dl ( woman serum creatinine &gt; 1.5 mg/dl must measure eighthour urine creatinine clearance &gt; 70 ml/min ) SGPT le 10 time upper limit normal NOTE : Women Grade 2 Grade 3 SGPT value ( 2.6 10 time upper limit normal ) allow study ; monitor monthly delivery . If point SGPT value rise Grade 4 ( 10 time upper limit normal ) , dose Study Drug . evidence preexist fetal anomaly incompatible life ; know hypersensitivity benzodiazepine NVP ; receipt antiretroviral agent ZDV ; receipt nonallowed concomitant treatment ; uncontrolled hypertension ; concurrent participation another clinical trial ; woman CD4 count &lt; 200/ÂµL history oral candidiasis receive PCP prophylaxis .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Thailand</keyword>
	<keyword>Developing country</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>mother child transmission</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>